CoChat

Hypothalamic orexin--a neurons are involved in the response of the brain stress system to morphine withdrawal

Open access

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Both the hypothalamus-pituitary-adrenal (HPA) axis and the extrahypothalamic brain stress system are key elements of the neural circuitry that regulates the negative states during abstinence from chronic drug exposure. Orexins have recently been hypothesized to modulate the extended amygdala and to contribute to the negative emotional state associated with dependence. This study examined the impact of chronic morphine and withdrawal on the lateral hypothalamic (LH) orexin A (OXA) gene expression and activity as well as OXA involvement in the brain stress response to morphine abstinence. Male Wistar rats received chronic morphine followed by naloxone to precipitate withdrawal. The selective OX1R antagonist SB334867 was used to examine whether orexins' activity is related to somatic symptoms of opiate withdrawal and alterations in HPA axis and extended amygdala in rats dependent on morphine. OXA mRNA was induced in the hypothalamus during morphine withdrawal, which was accompanied by activation of OXA neurons in the LH. Importantly, SB334867 attenuated the somatic symptoms of withdrawal, and reduced morphine withdrawal-induced c-Fos expression in the nucleus accumbens (NAc) shell, bed nucleus of stria terminalis, central amygdala and hypothalamic paraventricular nucleus, but did not modify the HPA axis activity. These results highlight a critical role of OXA signalling, via OX1R, in activation of brain stress system to morphine withdrawal and suggest that all orexinergic subpopulations in the lateral hypothalamic area contribute in this response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0036871

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Attenuation of the severity of somatic signs of naloxone-precipitated morphine withdrawal up to 30 min after the naloxone injection by SB-334867 pretreatment. The following variables were counting: (A) wet-dog shakes; (B) sniffing; (C) writhing; (D) body tremor; (E) ptosis; (F) diarrhoea; (G) piloerection; (H) mastication; (I) teeth chattering; (J) paw tremor; (K) body weight loss. Somatic signs of withdrawal were observed during 30 min immediately after naloxone injection (1 mg/kg s.c.) A global withdrawal score (L) was calculated for each animal as described in Methods. Data are expressed as mean ± SEM. *p<0.05; ***p<0.001, versus placebo + vehicle (veh) + naloxone (nx); ++p<0.01; +++p<0.001 versus similar groups receiving vehicle instead of SB-334867.
Figure 1 Attenuation of the severity of somatic signs of naloxone-precipitated morphine withdrawal up to 30 min after the naloxone injection by SB-334867 pretreatment. The following variables were counting: (A) wet-dog shakes; (B) sniffing; (C) writhing; (D) body tremor; (E) ptosis; (F) diarrhoea; (G) piloerection; (H) mastication; (I) teeth chattering; (J) paw tremor; (K) body weight loss. Somatic signs of withdrawal were observed during 30 min immediately after naloxone injection (1 mg/kg s.c.) A global withdrawal score (L) was calculated for each animal as described in Methods. Data are expressed as mean ± SEM. *p<0.05; ***p<0.001, versus placebo + vehicle (veh) + naloxone (nx); ++p<0.01; +++p<0.001 versus similar groups receiving vehicle instead of SB-334867.CC BY · PubMed Central
Figure 2 Morphine withdrawal induced OXA gene expression in the hypothalamus. Rats were sacrificed at different time-points (15, 30, 60 and 120 min) after saline or naloxone injection. Mean ± SEM RQ (relative quantification of the comparative CT experiments) expression values were obtained by real-time qPCR measurement, where the expression of OXA gene in morphine withdrawn rats is expressed relative to the placebo implanted controls receiving naloxone. ***p<0.001 versus placebo + naloxone; +++p<0.001 versus morphine + saline.
Figure 2 Morphine withdrawal induced OXA gene expression in the hypothalamus. Rats were sacrificed at different time-points (15, 30, 60 and 120 min) after saline or naloxone injection. Mean ± SEM RQ (relative quantification of the comparative CT experiments) expression values were obtained by real-time qPCR measurement, where the expression of OXA gene in morphine withdrawn rats is expressed relative to the placebo implanted controls receiving naloxone. ***p<0.001 versus placebo + naloxone; +++p<0.001 versus morphine + saline.CC BY · PubMed Central
Figure 3 Chronic morphine and morphine withdrawal do not modify the number of OXA neurons in the DMH, PFA and LLH regions of the lateral hypothalamus. Placebo and morphine-dependent groups were sacrificed 120 min after saline or naloxone administration. (A) Schematic anatomic representation of LH subdivisions adapted from Paxinos and Watson stereotaxic atlas [42]. (B–E, E′) Representative photographs illustrating regional orexin A cell expression in the LH. (F) Mean ± SEM in the three regions of the LH. 3V, third ventricle; f, fornix. Scale bars, 200 μm (B–E) and 20 μm (E′).
Figure 3 Chronic morphine and morphine withdrawal do not modify the number of OXA neurons in the DMH, PFA and LLH regions of the lateral hypothalamus. Placebo and morphine-dependent groups were sacrificed 120 min after saline or naloxone administration. (A) Schematic anatomic representation of LH subdivisions adapted from Paxinos and Watson stereotaxic atlas [42]. (B–E, E′) Representative photographs illustrating regional orexin A cell expression in the LH. (F) Mean ± SEM in the three regions of the LH. 3V, third ventricle; f, fornix. Scale bars, 200 μm (B–E) and 20 μm (E′).CC BY · PubMed Central
Figure 4 Naloxone-induced morphine withdrawal results in activation of orexin A cells in the DMH, PFA and in the LLH. (A–D) Representative photographs showing double-label immunohistochemistry for c-Fos and OXA in the LH. (D′) High magnification image showing c-Fos-positive (black)/OXA-positive (brown) neurons. 3V, third ventricle; f, fornix. Scale bars, 200 μm (A–D) and 50 μm (D′). Arrows indicate c-Fos in OXA-positive neurons. (E) Regional expression of c-Fos in OXA positive cells. Bars represent the mean ± SEM. +++p<0.001 versus morphine + saline; ***p<0.001 versus placebo + naloxone.
Figure 4 Naloxone-induced morphine withdrawal results in activation of orexin A cells in the DMH, PFA and in the LLH. (A–D) Representative photographs showing double-label immunohistochemistry for c-Fos and OXA in the LH. (D′) High magnification image showing c-Fos-positive (black)/OXA-positive (brown) neurons. 3V, third ventricle; f, fornix. Scale bars, 200 μm (A–D) and 50 μm (D′). Arrows indicate c-Fos in OXA-positive neurons. (E) Regional expression of c-Fos in OXA positive cells. Bars represent the mean ± SEM. +++p<0.001 versus morphine + saline; ***p<0.001 versus placebo + naloxone.CC BY · PubMed Central
Figure 5 Naloxone-induced morphine withdrawal results in activation of extended amygdala. SB-334867 attenuated c-Fos expression in the NAc, BNST and CeA in morphine-withdrawn rats. Rats were pretreated with the selective OX1R antagonist SB334867 20 min prior naloxone injection and were sacrificaed 120 min after naloxone administration. (A, D, G) Schematic anatomic representation of NAc shell, BNST and CeA adapted from Paxinos and Watson atlas (2007). Labeled areas delineate regions where c-Fos expression was examined. (B I) Representative photographs of c-Fos expression in the NAc, BNST (oval) and CeA in animals pretreated with morphine-vehicle-naloxone (B, E, H) or with morphine-SB-334867-naloxone (C, F, I). LV, lateral ventricle; ac, anterior comissure; BLA, basolateral amygdala. Scale bar, 200 µm. (J) Quantification of neurons expressing c-Fos in the NAc shell, BNST (oval) and CeA. Bars represent mean ± SEM. ***p<0.001 versus placebo + vehicle (veh) + naloxone (nx); ++p<0.01; +++p<0.001 versus placebo + SB-334867+ naloxone; ##p<0.01, ###p<0.001 versus morphine + vehicle + naloxone.
Figure 5 Naloxone-induced morphine withdrawal results in activation of extended amygdala. SB-334867 attenuated c-Fos expression in the NAc, BNST and CeA in morphine-withdrawn rats. Rats were pretreated with the selective OX1R antagonist SB334867 20 min prior naloxone injection and were sacrificaed 120 min after naloxone administration. (A, D, G) Schematic anatomic representation of NAc shell, BNST and CeA adapted from Paxinos and Watson atlas (2007). Labeled areas delineate regions where c-Fos expression was examined. (B I) Representative photographs of c-Fos expression in the NAc, BNST (oval) and CeA in animals pretreated with morphine-vehicle-naloxone (B, E, H) or with morphine-SB-334867-naloxone (C, F, I). LV, lateral ventricle; ac, anterior comissure; BLA, basolateral amygdala. Scale bar, 200 µm. (J) Quantification of neurons expressing c-Fos in the NAc shell, BNST (oval) and CeA. Bars represent mean ± SEM. ***p<0.001 versus placebo + vehicle (veh) + naloxone (nx); ++p<0.01; +++p<0.001 versus placebo + SB-334867+ naloxone; ##p<0.01, ###p<0.001 versus morphine + vehicle + naloxone.CC BY · PubMed Central
Figure 6 SB334867 attenuated naloxone-induced morphine withdrawal induction of c-Fos expression in the PVN but not in the NTS. (A, D) Schematic anatomic representation of the PVN and NTS adapted from Paxinos and Watson atlas (2007). Labelled areas delineate regions where c-Fos expression was examined. (B–F) Representative photographs of c-Fos expression in the PVN and NTS in animals pretreated with morphine-vehicle-naloxone (B, E) or with morphine-SB334867-naloxone (C, F). Animals were sacrificed 120 min after naloxone administration. 3V, third ventricle; AP, area postrema. Scale bar: 100 µm. (G) Quantification of neurons expressing c-Fos in the PVN (parvocellular subdivision) and in the NTS-A2 catecholaminergic cell group. Bars represent mean ± SEM. **p<0.01 ***p<0.001 versus placebo + vehicle (veh) + naloxone (nx); +p<0.05; ++p<0.01 versus placebo + SB-334867+ naloxone; ###p<0.001 versus morphine + vehicle + naloxone.
Figure 6 SB334867 attenuated naloxone-induced morphine withdrawal induction of c-Fos expression in the PVN but not in the NTS. (A, D) Schematic anatomic representation of the PVN and NTS adapted from Paxinos and Watson atlas (2007). Labelled areas delineate regions where c-Fos expression was examined. (B–F) Representative photographs of c-Fos expression in the PVN and NTS in animals pretreated with morphine-vehicle-naloxone (B, E) or with morphine-SB334867-naloxone (C, F). Animals were sacrificed 120 min after naloxone administration. 3V, third ventricle; AP, area postrema. Scale bar: 100 µm. (G) Quantification of neurons expressing c-Fos in the PVN (parvocellular subdivision) and in the NTS-A2 catecholaminergic cell group. Bars represent mean ± SEM. **p<0.01 ***p<0.001 versus placebo + vehicle (veh) + naloxone (nx); +p<0.05; ++p<0.01 versus placebo + SB-334867+ naloxone; ###p<0.001 versus morphine + vehicle + naloxone.CC BY · PubMed Central
Figure 7 Immunohistochemical localization of orexin A nerve fibers in the NTS, BNST, NAc, PVN and CeA in placebo-implanted control rats. Representative photographs showing double-label immunohistochemistry for TH and OXA (NTS, A), CRF and OXA (BNST, B; PVN, D; and CeA, E) and pro-DYN and OXA (NAc, C). Scale bar, 50 µm. Images depict the orexin A innervations (blue-black) of the CRF, pro-DYN and TH neurons (brown) in the extended amygdala, NTS and PVN. Higher magnification images of the boxes areas depicted in each photomicrograph show examples of the areas where OXA axons are opposed to the somata of CRF, TH and pro-DYN cells. Abbreviations: NTS, nucleus of the solitary tract; BNST, bed nucleus of the stria terminalis; NAc, nucleus accumbens; PVN, hypothalamic paraventricular nucleus; CeA, central amygdala; cc, canal central; 3V, third ventricle.
Figure 7 Immunohistochemical localization of orexin A nerve fibers in the NTS, BNST, NAc, PVN and CeA in placebo-implanted control rats. Representative photographs showing double-label immunohistochemistry for TH and OXA (NTS, A), CRF and OXA (BNST, B; PVN, D; and CeA, E) and pro-DYN and OXA (NAc, C). Scale bar, 50 µm. Images depict the orexin A innervations (blue-black) of the CRF, pro-DYN and TH neurons (brown) in the extended amygdala, NTS and PVN. Higher magnification images of the boxes areas depicted in each photomicrograph show examples of the areas where OXA axons are opposed to the somata of CRF, TH and pro-DYN cells. Abbreviations: NTS, nucleus of the solitary tract; BNST, bed nucleus of the stria terminalis; NAc, nucleus accumbens; PVN, hypothalamic paraventricular nucleus; CeA, central amygdala; cc, canal central; 3V, third ventricle.CC BY · PubMed Central
Figure 8 OX1R antagonist SB334867 attenuates activation of CRF-containing neurons in the CeA but not in either the PVN or the BNST. Microscopy showing double-label immunohistochemistry for c-Fos and CRF in the PVN (A–D), BNST (E, F) and CeA (G, H). (a–d): higher magnification from (A–D). Scale bars, 100 µm (A–H); 50 µm (a–d). (I): mean ± SEM. **p<0.01, ***p<0.001 versus placebo + vehicle + naloxone; +++p<0.001 versus placebo + SB334867 + naloxone; #p<0.05 versus morphine + vehicle + naloxone.
Figure 8 OX1R antagonist SB334867 attenuates activation of CRF-containing neurons in the CeA but not in either the PVN or the BNST. Microscopy showing double-label immunohistochemistry for c-Fos and CRF in the PVN (A–D), BNST (E, F) and CeA (G, H). (a–d): higher magnification from (A–D). Scale bars, 100 µm (A–H); 50 µm (a–d). (I): mean ± SEM. **p<0.01, ***p<0.001 versus placebo + vehicle + naloxone; +++p<0.001 versus placebo + SB334867 + naloxone; #p<0.05 versus morphine + vehicle + naloxone.CC BY · PubMed Central
Figure 9 Effects of OX1R antagonism on the morphine withdrawal-induced increase in plasma corticosterone levels. SB334867 did not attenuate the plasma corticosterone response to naloxone-induced morphine withdrawal. Data represent the mean ± SEM of corticosterone concentration 120 min after naloxone (nx) injection to placebo- or morphine-treated rats receiving vehicle (veh) or SB334867 (SB) 20 min before naloxone administration. Mean ± SEM. +p<0.05, +++p<0.001 versus placebo + vehicle + naloxone **p<0.01 versus morphine + vehicle + naloxone.
Figure 9 Effects of OX1R antagonism on the morphine withdrawal-induced increase in plasma corticosterone levels. SB334867 did not attenuate the plasma corticosterone response to naloxone-induced morphine withdrawal. Data represent the mean ± SEM of corticosterone concentration 120 min after naloxone (nx) injection to placebo- or morphine-treated rats receiving vehicle (veh) or SB334867 (SB) 20 min before naloxone administration. Mean ± SEM. +p<0.05, +++p<0.001 versus placebo + vehicle + naloxone **p<0.01 versus morphine + vehicle + naloxone.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 58

Metadata

Authors
Laorden, M. L., Ferenczi, S., Pintér-Kübler, B., González-Martín, L. L., Lasheras, M. C., Kovács, K. J., Milanés, M. V., & Núñez, C.
Affiliations
  • Instituto Murciano de Investigación Biosanitaria (ES)
  • HUN-REN Institute of Experimental Medicine (HU)
Corresponding author
Milanés, M. Victoria
Venue
PLoS ONE
Published
2012-05-09
Volume
7
Issue
5
Pages
e36871
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1981813055
Cited by
55
References
43
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 1 · 2014: 10 · 2013: 8 · 2012: 1
FWCI
2.64
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Hungarian Scientific Research Fund
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
orexin-A, morphine withdrawal, lateral hypothalamus, OX1 receptor, SB-334867, hypothalamic-pituitary-adrenal axis, extended amygdala, opioid use disorder, naloxone-precipitated withdrawal, Fos expression, nucleus accumbens shell, bed nucleus of the stria terminalis, central amygdala, paraventricular nucleus
MeSH terms
Orexins, Amygdala, Animals, Hypothalamo-Hypophyseal System, Male, Morphine, Morphine Dependence, Narcotics, Neurons, Neuropeptides, Paraventricular Hypothalamic Nucleus, Pituitary-Adrenal System, Substance Withdrawal Syndrome, Rats, Wistar, Receptors, Neuropeptide, Receptors, G-Protein-Coupled, Intracellular Signaling Peptides and Proteins, Rats, Orexin Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypothalamic orexin--a neurons are involved in the response of the brain stress system to morphine withdrawal. https://app.cochat.ai/papers/10.1371/journal.pone.0036871
The paper
Laorden, M. L., Ferenczi, S., Pintér-Kübler, B., González-Martín, L. L., Lasheras, M. C., Kovács, K. J., Milanés, M. V., & Núñez, C. (2012). Hypothalamic orexin--a neurons are involved in the response of the brain stress system to morphine withdrawal. PLoS ONE. https://doi.org/10.1371/journal.pone.0036871

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.